Abstract: Human TNF muteins having higher binding affinity for human p75-TNF receptor than for human p55-TNF receptor include muteins having at least one different amino acid relative to wild-type human TNF at a position corresponding to position 33, 65, 67, 75, 87, 143, 145 or 147 of the wild-type amino acid sequence.

Abstract: Human interleukin 2 (IL-2) derived from induced human malignant cells has been purified to homogeneity using multiple high performance liquid chromatography (HPLC) steps. The purified IL-2 exhibits potent activity promoting the long-term in vitro culture of antigen-specific effector T-lymphocytes and in modulating lymphocyte reactivity.

Abstract: The present invention is a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of producing an immunogenic response possessed by the protein which forms this conjugate.

Abstract: Compounds of the formula ##STR1## wherein L, M, R, T and X are set forth in the description, as well as hydrates or solvates thereof, which inhibit thrombin-induced platelet aggregation and clotting of fibrinogen in plasma, are described. The compounds of formula I are prepared by amidination or, depending on whether L is NH or O, by amide formation or esterification.

Abstract: An intact human immune interferon protein and a method for the extraction and purification of intact recombinant human immune interferon is disclosed. This method permits the purification to homogeneity of intact recombinant human immune interferon.

Abstract: The present invention is directed to oligodeoxynucleotides which are capable of hybridizing to genes which encode NF-.kappa.B. The oligodeoxyribonucleotides are antisense to NF.kappa.B genes and when hybridized prevent the production of NF.kappa.B transcription factor by the NF.kappa.B genes, and thereby provide a means for preventing cellular adhesion.

Abstract: A process for the preparation of a halogenated .alpha.

Abstract: Compounds of the formula ##STR1## wherein L, M, R, T and X are set forth in the description, as well as hydrates or solvates thereof, which inhibit thrombin-induced platelet aggregation and clotting of fibrinogen in plasma, are described. The compounds of formula I are prepared by amidination or, depending on whether L is NH or O, by amide formation or esterification.

Abstract: Compounds of the formula: ##STR1## wherein R.sup.1 is alkoxycarbonyl, aralkoxycarbonyl, alkanoyl, aralkanoyl, heterocyclylcarbonyl or a group of the formula: ##STR2## R.sup.2 is alkyl, cycloalkylalkyl or aralkyl; R.sup.3 is hydrogen and R.sup.4 is hydroxy or R.sup.3 and R.sup.4 together are oxo; R.sup.5 is alkoxycarbonyl or alkylcarbamoyl; R.sup.6 and R.sup.7 together are trimethylene or tetramethylene optionally substituted by alkyl or on adjacent carbon atoms by tetramethylene; R.sup.8 is alkoxycarbonyl, aralkoxycarbonyl, alkanoyl, aroyl, aralkanoyl or heteroeyelylearbonyl; and R.sup.9 is alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, cyanoalkyl, carbamoyl-alkyl, alkylthioalkyl, alkoxyalkyl or alkoxycarbonylalkyl:and pharmaceutically acceptable acid addition salts of those compounds of formula I which are basic, inhibit aspartyl proteases of viral origin and can be used in the form of medicaments for the prophylaxis or treatment of viral infections.

Abstract: Novel alcohols of the formula ##STR1## wherein R.sup.a is azido or phthalimido, R.sup.4 is alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl, R.sup.7 and R.sup.8 together are a trimethylene or tetramethylene group which is optionally substituted by hydroxy, alkoxycarbonylamino or acylamino or in which one --CH.sub.2 -- group is replaced by --NH--, -N(alkoxycarbonyl)-,-N(acyl)- or --S--or which carries a fused cycloalkane, aromatic or heteroaromatic ring, and R.sup.9 is alkoxycarbonyl, monoalkylcarbamoyl, monoaralkylcarbamoyl, monoarylcarbamoyl or a group of the formula ##STR2## in which R.sup.10 and R.sup.11 each is alkyl, are described along with a process for their manufacture. These alcohols are useful as intermediates, for example in the manufacture of amino acid derivatives having antiviral activity.

Abstract: A process for the production of a .beta.-aminoalcohol 2-[3(S)-amino-2-hydroxy-4-phenylbutyl]-N-tert.butyl-decahydro-(4aS,8aS)-is oquinoline-3(S)-carboxamide of the formula ##STR1## via the oxazolidinone corresponding to the aminoalcohol 10 which process comprises refluxing a sulphonic acid ester with a carboxamide in the presence of a base and a solvent.

Abstract: A process for the detection of a nucleic acid sequence in a homogeneous assay format using an energy transfer system is disclosed. This process utilizes a 5' labeled primer containing a selfcomplementary sequence in an amplification or extension process together with a subsequent detection step using a 3' labeled probe for the amplified or extended region. The labels will be close together in space after hybridizing the probe close to the short piece of double-stranded DNA resulting from backfolding of the selfcomplementary region of the primer which has been incorporated into the amplified or extended product. A new primer for use in this process is also disclosed.

Abstract: A cell for performing optical measurements in an automatic analyzer is molded in one piece from a transparent plastic material, and has a tubular body including two plane walls parallel to each other, two opposite ends, and a bottom wall. The first end of the tubular body is open and the second end is closed by the bottom wall which has the shape of a half-cylinder. The tubular body of the cell has two side-walls which extend between the plane-parallel walls and which each have an upper portion and a lower portion. The lower portion of each side wall is adjacent the bottom wall and includes an elongated, leg-shaped outer projection which extends along the longitudinal axis of the cell between the upper portion of the side-wall and a point at a certain distance from the bottom wall. Each of the plane-parallel walls has a tongue member adjacent the open end of the tubular body.

Abstract: Novel alcohols of the formula ##STR1## wherein R.sup.a is azido or phthalimido, R.sup.4 is alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl, R.sup.7 and R.sup.8 together are a trimethylene or tetramethylene group which is optionally substituted by hydroxy, alkoxycarbonylamino or acylamino or in which one --CH.sub.2 -- group is replaced by --NH--, --N(alkoxycarbonyl)--, --N(acyl)-- or --S-- or which carries a fused cycloalkane, aromatic or heteroaromatic ring, and R.sup.9 is alkoxycarbonyl, monoalkylcarbamoyl, monoaralkylcarbamoyl, monoarylcarbamoyl or a group of the formula ##STR2## in which R.sup.10 and R.sup.11 each is alkyl, are described along with a process for their manufacture. These alcohols are useful as intermediates, for example in the manufacture of amino acid derivatives having antiviral activity.

Abstract: The novel carboxamides of the formula ##STR1## wherein A, E, G, L, M, R and Q have the significance given in the description, as well as hydrates or solvates thereof inhibit thrombin-induced platelet aggregation and fibrinogen coagulation in plasma. They can be manufactured starting from the corresponding acid and the corresponding amine H.sub.2 NCH.sub.2 Q.

Abstract: The present invention is a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of producing an immunogenic response possessed by the protein which forms this conjugate.

Abstract: Methods, reagents and kits are provided for simultaneously amplifying and detecting polynucleotide sequences in bacteria causing Neisseria gonorrhoeae and/or Chlamydia trachomatis using primers and probes specific for each bacterial species.

Abstract: The present invention is concerned with a process for the manufacture of optically active compounds of the formula ##STR1## wherein R signifies lower alkyl, lower alkoxy, phenyl, benzyl or --NR.sub.2.sup.1, R.sup.1 signifies lower alkyl, phenyl, benzyl or hydrogen and * signifies an optically active center, by asymmetrically hydrogenating an enol derivative of ketoisophorone of the formula ##STR2## wherein R has the significance given above, in the presence of a rhodium complex of an optically active diphosphine ligand.

Abstract: Novel antigenic polypeptides having at least one determinant immunologically cross-reactive with determinants on a polypeptide associated with the rhoptry organelles of the merozoite form of the malaria parasite Plasmodium falciparum are described. Also described are immunogenic compositions containing such a polypeptide, DNAs coding for such a polypeptide, recombinant vectors containing such a DNA sequence, host organisms containing a replicable vector, and antibodies which are directed against a polypeptide in accordance with the invention. In addition, processes for the production of the immunogenic compositions, the microorganisms, and the antibodies, as well as the use the polypeptides and the immunogenic compositions for the immunization of mammals against malaria are also described.

Abstract: A process for producing 2-keto-L-gulonic acid which comprises converting L-sorbose and/or D-sorbitol into 2-keto-L-gulonic acid with the aid of a microorganism or its cell free extract, said microorganism belonging to the species Gluconobacter oxydans capable of producing 2-keto-L-gulonic acid and having L-sorbose dehydrogenase activity. Also disclosed are specific microorganisms useful in such process.